SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Dr Reddy’s Outlook Could Improve With Semaglutide Generic, Biosimilars

Dr Reddy’s domestic formulations business grew in the September quarter, offset by lower Revlimid sales in North America and weakness in its API business. The body is truncated before providing further details.

DRREDDY

Related stories